Zessly

Zessly is an infliximab biosimilar developed by Sandoz, a division of Novartis, designed to treat various inflammatory and autoimmune conditions. As a chimeric monoclonal antibody, it acts as a tumor necrosis factor alpha (TNF-α) inhibitor. It binds with high affinity to both soluble and transmembrane forms of TNF-α, preventing the cytokine from interacting with its receptors and thereby neutralizing its pro-inflammatory activity. Zessly received European Commission approval in May 2018 as a biosimilar to the reference medicine Remicade. It is indicated for use in adult and pediatric patients with Crohn's disease, as well as those with ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Brand names

Zessly

Other names

infliximab